Could we make stem cell transplants safer simply by training the immune system first? New research suggests we can—and it could transform the future of blood cancer care. But here's where it gets controversial: instead of suppressing the immune response after a transplant, scientists are learning how to prepare it in advance.
Researchers at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have uncovered a groundbreaking approach that significantly reduces complications after stem cell transplants for blood cancer patients. Their study shows that priming the body with a treatment designed to expand regulatory T cells—commonly known as Tregs—before the procedure may greatly improve patient survival, strengthen organs, and support a balanced, healthy gut microbiome.
Tackling one of the biggest transplant risks
Allogeneic haematopoietic stem cell transplantation (aHSCT) is a life-saving option for many battling blood cancers and other serious illnesses. Yet it carries a serious danger—graft-versus-host disease (GVHD), a condition in which the donor’s immune cells mistakenly attack the patient's tissues. Standard care often uses powerful immunosuppressants to control this reaction, but these drugs can create new problems, such as making patients more prone to severe infections.
So what if, instead of silencing the immune system, doctors could teach it to behave appropriately before the transplant even happens? That’s the new direction this research explores.
A smarter way to regulate the immune response
The Sylvester team developed a method to expand the body’s population of regulatory T cells—these are the peacekeepers of the immune system, preventing it from spiraling into harmful inflammation.
“Our method helps the body create a friendlier environment for incoming stem cells,” explained Dr. Robert Levy, Professor of Microbiology and Immunology at the Miller School and lead researcher of the study. “Rather than merely suppressing immunity, we’re guiding it in the right direction to support recovery.”
To achieve this, the researchers combined TL1A-Ig fusion protein with small doses of IL-2, activating two receptors—TNFRSF25 and CD25—on Tregs. This activation encouraged the protective cells to multiply and travel to key organs like the liver, colon, and eyes—areas often damaged in GVHD.
Healthier outcomes and a resilient gut
In preclinical studies, the approach showed remarkable benefits:
- Increased survival rates
- Less severe GVHD symptoms and reduced weight loss
- Stronger colon and liver tissue integrity
- A richer, more stable gut microbiome
Dr. Levy noted, “When we grew Tregs before transplantation, we saw better organ protection and a balanced microbiome—essentially, the immune system became a stronger ally rather than a threat.”
Importantly, the treatment did not interfere with the graft-versus-leukaemia (GVL) effect—the very immune attack that eliminates lingering cancer cells. That balance between protection and cancer-fighting power could be the key to long-term success.
A major step toward personalized care
Traditional transplant methods often involve manipulating donor cells outside the body—a complex and expensive process. This new approach works entirely inside the patient (in vivo), making it more practical, cost-effective, and potentially accessible to far more people.
“Personalized medicine isn’t just about genetics,” said Dr. Levy. “It’s about equipping the body to recover naturally. By nurturing both the immune system and the microbiome, we’re creating a transplant environment that helps patients heal faster and more effectively.”
The research team now aims to move this method into clinical trials, bringing it closer to use in hospitals and treatment centers. If successful, pre-transplant Treg therapy could become a standard step in preparing patients for safer transplants.
Dr. Levy concluded, “This is about restoring balance—training the immune system to protect, not attack. Each discovery gets us closer to making transplants safer and more accessible for patients everywhere.”
Could this approach redefine how we think about immune control in medicine? Or do the unknowns of immune manipulation make you cautious? Share your thoughts—should we guide the immune system or continue controlling it by force?
